Andrew Benjamin Nixon, PhD

Professor in Medicine
Member of the Duke Cancer Institute
Campus mail 133 Jones, Research Drive, Durham, NC 27710
Phone (919) 613-7883
Email address anixon@duke.edu

Andrew Nixon, PhD, MBA (Associate Professor of Medicine) is Director of the Phase I Biomarker Laboratory, which brings together clinical, translational and basic research to pursue the development of novel biomarkers defining mechanisms of sensitivity, resistance, and toxicity to given therapeutic drug classes, particularly anti-angiogenic agents. Additionally, the laboratory has been appointed as a Molecular Reference Laboratory for the Alliance oncology cooperative group, a national clinical trial research group sponsored by the National Cancer Institute. The laboratory has quality control procedures in place to address many of the issues involved in clinical trial research including determination of sample quantity, sample integrity, and sample heterogeneity. We have spent considerable time developing robust assays that utilize limited amounts of specimen while providing high quality data. Multiplex ELISA and gene expression arrays are used to analyze serially collected blood and paraffin samples archived from cancer patient clinical trials. This work has the potential to improve the efficacy and toxicity of current therapies and to guide the development of the next generation of anti-angiogenesis therapies for cancer and other diseases.

Education and Training

  • Ph.D., Wake Forest University, 1997

Publications

Gbenedio, Oghenekevwe M., Caroline Bonnans, Delphine Grun, Chih-Yang Wang, Ace J. Hatch, Michelle R. Mahoney, David Barras, et al. “RasGRP1 is a potential biomarker to stratify anti-EGFR therapy response in colorectal cancer.” Jci Insight 5 (June 25, 2019). https://doi.org/10.1172/jci.insight.127552.

PMID
31237864
Full Text

Lin, Jiaxing, Alexander Sibley, Ivo Shterev, Andrew Nixon, Federico Innocenti, Cliburn Chan, and Kouros Owzar. “fastJT: An R package for robust and efficient feature selection for machine learning and genome-wide association studies.” Bmc Bioinformatics 20, no. 1 (June 13, 2019): 333. https://doi.org/10.1186/s12859-019-2869-3.

PMID
31195980
Full Text

Kelly, Francine L., Kaitlyn E. Weinberg, Andrew E. Nagler, Andrew B. Nixon, Mark D. Star, Jamie L. Todd, David M. Brass, and Scott M. Palmer. “EGFR-Dependent IL8 Production by Airway Epithelial Cells After Exposure to the Food Flavoring Chemical 2,3-Butanedione.” Toxicol Sci 169, no. 2 (June 1, 2019): 534–42. https://doi.org/10.1093/toxsci/kfz066.

PMID
30851105
Full Text

Secord, Angeles Alvarez, Michael McCollum, Brittany A. Davidson, Gloria Broadwater, Robert Squatrito, Laura J. Havrilesky, Anne C. Gabel, et al. “Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.” Gynecol Oncol 153, no. 3 (June 2019): 555–61. https://doi.org/10.1016/j.ygyno.2019.03.246.

PMID
30929823
Full Text

Mettu, Niharika B., Donna Niedzwiecki, Christel Rushing, Andrew B. Nixon, Jingquan Jia, Sherri Haley, Wanda Honeycutt, Herbert Hurwitz, Johanna C. Bendell, and Hope Uronis. “A phase I study of gemcitabine + dasatinib (gd) or gemcitabine + dasatinib + cetuximab (GDC) in refractory solid tumors.” In Cancer Chemotherapy and Pharmacology, 83:1025–35, 2019. https://doi.org/10.1007/s00280-019-03805-6.

PMID
30895346
Full Text

Isaacs, James, Andrew B. Nixon, Emily Bolch, Katie Quinn, Kimberly Banks, Brent Allen Hanks, and John H. Strickler. “Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.” In Journal of Clinical Oncology, 37:3552–3552. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.3552.

Full Text

Bergsland, Emily K., Michelle R. Mahoney, Timothy R. Asmis, Nathan Hall, Priya Kumthekar, Michael L. Maitland, Donna Niedzwiecki, et al. “Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (CARC) (Alliance A021202).” In Journal of Clinical Oncology, 37:4005–4005. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4005.

Full Text

Sinicrope, Frank A., Fang-Shu Ou, Tyler Zemla, Andrew B. Nixon, Kabir Mody, Alexandra Levasseur, Amylou C. Dueck, et al. “Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502).” In Journal of Clinical Oncology, 37:e15169–e15169. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.e15169.

Full Text

Guercio, Brendan John, Alan P. Venook, Sui Zhang, Fang-Shu Ou, Donna Niedzwiecki, Heinz-Josef Lenz, Federico Innocenti, et al. “Associations of insulin-like growth factor binding proteins and adiponectin with disease progression and mortality in metastatic colorectal cancer: Results from CALGB/SWOG 80405 (Alliance).” In Journal of Clinical Oncology, 37:3035–3035. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.3035.

Full Text

Kim, Dae Won, Hanna Kelly Sanoff, Andrew Stewart Poklepovic, Fatima Tariq, Andrew B. Nixon, Yingmiao Liu, and Richard D. Kim. “Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).” In Journal of Clinical Oncology, 37:4083–4083. American Society of Clinical Oncology (ASCO), 2019. https://doi.org/10.1200/jco.2019.37.15_suppl.4083.

Full Text

Pages